RESUMEN
We tested Pfmrk against several naphthalene and isoquinoline sulfonamides previously reported as protein kinase A (PKA) inhibitors. Pfmrk is a Cyclin Dependent protein Kinase (CDK) from Plasmodium falciparum, the causative parasite of the most lethal form of malaria. We find that the isoquinoline sulfonamides are potent inhibitors of Pfmrk and that substitution on the 5 position of the isoquinoline ring greatly influences the degree of potency. Molecular modeling studies suggest that the nitrogen atom in the isoquinoline ring plays a key role in ligand-receptor interactions. Structural analysis suggests that even subtle differences in amino acid composition within the active sites are responsible for conferring specificity of these inhibitors for Pfmrk over PKA.
Asunto(s)
Quinasas Ciclina-Dependientes/metabolismo , Evaluación Preclínica de Medicamentos , Malaria/tratamiento farmacológico , Plasmodium falciparum/metabolismo , Animales , Sitios de Unión , Cristalografía por Rayos X , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Concentración 50 Inhibidora , Ligandos , Conformación Molecular , Naftalenos/metabolismo , Sulfonamidas/químicaRESUMEN
The development and spread of highly drug-resistant parasites pose a central problem in the control of malaria. Understanding mechanisms that regulate genomic stability, such as DNA repair, in drug-resistant parasites and during drug treatment may help determine whether this rapid onset of resistance is due to an increase in the rate at which resistance-causing mutations are generated. This is the first report to demonstrate DNA repair activities from the malaria-causing parasite Plasmodium falciparum that are specific for ultraviolet light-induced DNA damage. The efficiency of DNA repair differs dramatically among P. falciparum strains with varying drug sensitivities. Most notable is the markedly reduced level of repair in the highly drug-resistant W2 isolate, which has been shown to develop resistance to novel drugs at an increased rate when compared to drug-sensitive strains. Additionally, the antimalarial drug chloroquine and other quinoline-like compounds interfered with the DNA synthesis step of the repair process, most likely a result of direct binding to repair substrates. We propose that altered DNA repair, either through defective repair mechanisms or drug-mediated inhibition, may contribute to the accelerated development of drug resistance in the parasite.
Asunto(s)
Antimaláricos/uso terapéutico , Cloroquina/farmacología , Reparación del ADN , Resistencia a Medicamentos , Plasmodium falciparum/efectos de los fármacos , Animales , Antimaláricos/farmacología , Artemisininas/farmacología , Artemisininas/uso terapéutico , Cloroquina/metabolismo , Daño del ADN/efectos de la radiación , Resistencia a Múltiples Medicamentos , Humanos , Malaria Falciparum/tratamiento farmacológico , Mefloquina/farmacología , Mefloquina/uso terapéutico , Pruebas de Sensibilidad Parasitaria , Fenantrenos/farmacología , Fenantrenos/uso terapéutico , Pirimetamina/farmacología , Pirimetamina/uso terapéutico , Quinina/farmacología , Quinina/uso terapéutico , Sesquiterpenos/farmacología , Sesquiterpenos/uso terapéutico , Sulfanilamida , Sulfanilamidas/farmacología , Sulfanilamidas/uso terapéutico , Rayos UltravioletaRESUMEN
Cyclin-dependent protein kinases (CDKs) have been attractive drug targets for the development of anticancer therapies due to their direct and crucial role in the regulation of cellular proliferation. Following this trend, CDKs have been pursued as potential drug targets for several other diseases. Structure-based drug design programmes have focused on the plasmodial CDKs to develop new candidate antimalarial compounds. This review discusses the most recent advances relating to three Plasmodium falciparum CDKs (PfPK5, PfPK6 and Pfmrk) as they are developed as antimalarial drug targets. CDKs are highly conserved, and focus must be placed upon the amino acid differences between human and plasmodial CDKs in order to develop specific inhibitors. Comparisons of the active sites of human and parasite CDKs reveal sequence and potential structural variations. Using sequence analysis, molecular modelling and in vitro drug screening, it is possible to identify and develop inhibitors that specifically target the plasmodial CDKs. These efforts are aimed at identifying new classes of CDK inhibitors that may be exploited for antimalarial drug development.